Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria

Advanced Drug Delivery Reviews

Volumn 78, Issue , 2014, Pages 3-13

  Tang, Sarah S ^a   Apisarnthanarak, Anucha ^b   Hsu, Li Yang ^c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b THAMMASAT UNIVERSITY HOSPITAL   (Thailand)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Acinetobacter baumannii; Antimicrobial resistance; Carbapenem resistance; Enterobacteriaceae; Methicillin resistant Staphylococcus aureus; Vancomycin resistant enterococci; Lactamases

Indexed keywords

ANTIBIOTICS; DISEASES; HEALTH CARE;

ANTIMICROBIAL RESISTANCES; BAUMANNII; CARBAPENEMS; ENTEROBACTERIACEAE; LACTAMASES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; VANCOMYCIN-RESISTANT ENTEROCOCCI;

BACTERIA;

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; COMMUNITY ACQUIRED INFECTION; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; EPIDEMIOLOGY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HEALTHCARE ASSOCIATED INFECTION; HUMAN; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANIMAL; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HEALTH; ISOLATION AND PURIFICATION; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GLOBAL HEALTH; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 84919491854     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.08.003     Document Type: Review

References (151)

1. Ferriman A. BMJ readers choose the "sanitary revolution" as greatest medical advance since 1840. BMJ 2007, 334:111.2.
2. Fleming A. Nobel Lecture: Penicillin Available at:, (Last accessed: 6 May 2014). http://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdf.
3. Talbot G.H., Bradley J., Edwards J.E., Gilbert D., Scheld M., Bartlett J.G. Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 2006, 42:657-668.
4. World Economic Forum Insight Report: Global Risks 2013 Eighth Edition Available at:, (Last accessed: 6 May 2014). http://www3.weforum.org/docs/WEF_GlobalRisks_Report_2013.pdf.
5. Laxminarayan R., Duse A., Wattal C., Zaidi A.K., Wertheim H.F., Sumpradit N., Vlieghe E., Hara G.L., Gould I.M., Goossens H., Greko C., So A.D., Bigdeli M., Tomson G., Woodhouse W., Ombaka E., Peralta A.Q., Qamar F.N., Mir F., Kariuki S., Bhutta Z.A., Coates A., Bergstrom R., Wright G.D., Brown E.D., Cars O. Antibiotic resistance - the need for global solutions. Lancet Infect. Dis. 2013, 13:1057-1098.
6. Davies J., Davies D. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 2010, 74:417-433.
7. Livermore D.M. Bacterial resistance: origins, epidemiology, and impact. Clin. Infect. Dis. 2003, 36(Suppl. 1):S11-S23.
8. Maiden M.C. Horizontal genetic exchange, evolution, and spread of antibiotic resistance in bacteria. Clin. Infect. Dis. 1998, 27(Suppl. 1):S12-S20.
9. Ochman H., Lawrence J.G., Groisman E.A. Lateral gene transfer and the nature of bacterial innovation. Nature 2000, 405:299-304.
10. Levy S.B., Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 2004, 10(12 Suppl.):S122-S129.
11. Beceiro A., Tomás M., Bou G. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?. Clin. Microbiol. Rev. 2013, 26:185-230.
12. Aminov R.I. A brief history of the antibiotic era: lessons learned and challenges for the future. Front. Microbiol. 2010, 1:134.
13. Cloutier M.J. Antibiotics: mechanisms of action and the acquisition of resistance - when magic bullets lose their magic. Am. J. Pharm. Educ. 1995, 59:167-172.
14. Peleg A.Y., Hooper D.C. Hospital-acquired infections due to gram-negative bacteria. N. Engl. J. Med. 2010, 362:1804-1813.
15. Jorgensen J.H., Ferraro M.J. Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Clin. Infect. Dis. 2009, 49:1749-1755.
16. European Committee on Antimicrobial Susceptibility Testing Clinical Breakpoints Available at:, (Last accessed: 6 May 2014). http://www.eucast.org/clinical_breakpoints/.
17. Clinical and Laboratory Standards Institute Microbiology Standards Available at:, (Last accessed: 6 May 2014). http://clsi.org/standards/micro/.
18. Holden M.T., Hsu L.Y., Kurt K., Weinert L.A., Mather A.E., Harris S.R., Strommenger B., Layer F., Witte W., de Lencastre H., Skov R., Westh H., Zemlicková H., Coombs G., Kearns A.M., Hill R.L., Edgeworth J., Gould I., Gant V., Cooke J., Edwards G.F., McAdam P.R., Templeton K.E., McCann A., Zhou Z., Castillo-Ramírez S., Feil E.J., Hudson L.O., Enright M.C., Balloux F., Aanensen D.M., Spratt B.G., Fitzgerald J.R., Parkhill J., Achtman M., Bentley S.D., Nübel U. A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant Staphylococcus aureus pandemic. Genome Res. 2013, 23:653-664.
19. Martin C.M., Kunin C.M., Gottlieb L.S., Finland M. Asian influenza A in Boston, 1957-1958. II. Severe staphylococcal pneumonia complicating influenza. AMA Arch. Intern. Med. 1959, 103:532-542.
20. Lowy F.D. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Invest. 2003, 111:1265-1273.
21. Zhang H.Z., Hackbarth C.J., Chansky K.M., Chambers H.F. A proteolytic transmembrane signaling pathway and resistance to beta-lactams in staphylococci. Science 2001, 291:1962-1965.
22. Jevons M.P., Coe A., Parker M.T. Methicillin resistance in staphylococci. Lancet 1963, 1:904-907.
23. Hartman A., Tomasz B. Altered penicillin-binding proteins in methicillin-resistant strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 1991, 19:726-735.
24. Wang L., Archer G.L. Roles of ccrA and ccrB in excision and integration of staphylococcal cassette chromosome mec, a Staphylococcus aureus genomic island. J. Bacteriol. 2010, 192:3204-3212.
25. Pinho M.G., de Lencastre H., Tomasz A. An acquired and a native penicillin-binding protein cooperate in building the cell wall of drug-resistant staphylococci. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10886-10891.
26. Chambers H.F. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin. Microbiol. Rev. 1997, 10:781-791.
27. Komatsuzawa H., Ohta K., Labischinski H., Sugai M., Suginaka H. Characterization of fmtA, a gene that modulates the expression of methicillin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 1999, 43:2121-2125.
28. Leclercq R. Enterococci acquire new kinds of resistance. Clin. Infect. Dis. 1997, 24(Suppl. 1):S80-S84.
29. Hollenbeck B.L., Rice L.B. Intrinsic and acquired resistance mechanisms in Enterococcus. Virulence 2012, 35:421-433.
30. Sifaoui F., Arthur M., Rice L., Gutmann L. Role of penicillin-binding protein 5 in expression of ampicillin resistance and peptidoglycan structure in Enterococcus faecium. Antimicrob. Agents Chemother. 2001, 45:2594-2597.
31. Comenge Y., Quintiliani R., Li L., Dubost L., Brouard J.P., Hugonnet J.E., Arthur M. The CroRS two-component regulatory system is required for intrinsic beta-lactam resistance in Enterococcus faecalis. J. Bacteriol. 2003, 185:7184-7192.
32. Kristich C.J., Little J.L., Hall C.L., Hoff J.S. Reciprocal regulation of cephalosporin resistance in Enterococcus faecalis. MBio 2011, 2. e00199-11.
33. Hall C.L., Tschannen M., Worthey E.A., Kristich C.J. IreB, a Ser/Thr kinase substrate, influences antimicrobial resistance in Enterococcus faecalis. Antimicrob. Agents Chemother. 2013, 57:6179-6186.
34. Fontana R., Aldegheri M., Ligozzi M., Lopez H., Sucari A., Satta G. Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 1994, 38:1980-1983.
35. Turk S., Verlaine O., Gerards T., Zivec M., Humljan J., Sosič I., Amoroso A., Zervosen A., Luxen A., Joris B., Gobec S. New noncovalent inhibitors of penicillin-binding proteins from penicillin-resistant bacteria. PLoS ONE 2011, 6:e19418.
36. Dive G., Bouillon C., Sliwa A., Valet B., Verlaine O., Sauvage E., Marchand-Brynaert J. Macrocycle-embedded β-lactams as novel inhibitors of the penicillin binding protein PBP2a from MRSA. Eur. J. Med. Chem. 2013, 64:365-376.
37. Hao H., Cheng G., Dai M., Wu Q., Yuan Z. Inhibitors targeting on cell wall biosynthesis pathway of MRSA. Mol. BioSyst. 2012, 8:2828-2838.
38. Kumar K., Chopra S. New drugs for methicillin-resistant Staphylococcus aureus: an update. J. Antimicrob. Chemother. 2013, 68:1465-1470.
39. Pitout J.D.D., Sanders C.C., Sanders E. Antimicrobial resistance with focus on β-lactam resistance in gram-negative bacilli. Am. J. Med. 1997, 103:51-59.
40. Abraham E.P., Chain E. An enzyme from bacteria able to destroy penicillin. Nature 1940, 146:837.
41. Hall B.G., Barlow M. Revised Ambler classification of β-lactamases. J. Antimicrob. Chemother. 2005, 55:1050-1051.
42. Bush K., Jacoby G.A. Updated functional classification of β-lactamases. Antimicrob. Agents Chemother. 2010, 54:969-976.
43. Nordmann P. Trends in β-lactam resistance among Enterobacteriaceae. Clin. Infect. Dis. 1998, 27(Suppl. 1):S100-S106.
44. Jacoby G.A., Munoz-Price L.S. The new β-lactamases. N. Engl. J. Med. 2005, 352:380-391.
45. Jacoby G.A. AmpC β-lactamases. Clin. Microbiol. Rev. 2009, 22:161-182.
46. Paterson D.L., Bonomo R.A. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 2005, 18:657-686.
47. Pfeifer Y., Cullik A., Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int. J. Med. Microbiol. 2010, 300:371-379.
48. Paterson D.L. Resistance in gram-negative bacteria: Enterobacteriaceae. Am. J. Infect. Control 2006, 34(5 Suppl. 1):S20-S28.
49. Zhao W.H., Hu Z.Q. Epidemiology and genetics of CTX-M extended-spectrum β-lactamases in Gram-negative bacteria. Crit. Rev. Microbiol. 2013, 39:79-101.
50. Livermore D.M., Woodford N. The β-lactamase threat in Enterobacteriaceae. Pseudomonas and Acinetobacter. Trends Microbiol. 2006, 14:413-420.
51. CDC Antibiotic Resistance Threats in the United States, 2013 (Accessed 6th December 2013). http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.
52. Walter-Rasmussen J., Hoiby N. OXA-type carbapenemases. J. Antimicrob. Chemother. 2006, 57:373-383.
53. Walsh T.R. Clinically significant carbapenemases: an update. Curr. Opin. Infect. Dis. 2008, 21:367-371.
54. Corvec S., Caroff N., Espaze E., Giraudeau C., Drugeon H., Reynaud A. AmpC cephalosporinase hyperproduction in Acinetobacter baumanii clinical strains. J. Antimicrob. Chemother. 2003, 52:629-635.
55. Hamidian M., Hancock D.P., Hall R.M. Horizontal transfer of an ISAba125-activated AmpC gene between Acinetobacter baumannii strains leading to cephalosporin resistance. J. Antimicrob. Chemother. 2013, 68:244-245.
56. Rodríguez-Martínez J.M., Nordmann P., Ronco E., Poirel L. Extended-spectrum cephalosporinase in Acinetobacter baumannii. Antimicrob. Agents Chemother. 2010, 54:3484-3488.
57. Tian G.B., Adams-Haduch J.M., Taracila M., Bonomo R.A., Wang H.N., Doi Y. Extended-spectrum AmpC cephalosporinase in Acinetobacter baumannii: ADC-56 confers resistance to cefepime. Antimicrob. Agents Chemother. 2011, 55:4922-4925.
58. Turton J.F., Ward M.E., Woodford N., Kaufmann M.E., Pike R., Livermore D.M., Pitt T.L. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol. Lett. 2006, 258:72-77.
59. Krizova L., Poirel L., Nordmann P., Nemec A. TEM-1 β-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii. J. Antimicrob. Chemother. 2013, 68:2786-2791.
60. Poirel L., Bonnin R.A., Nordmann P. Genetic basis of antibiotic resistance in pathogenic Acinetobacter species. IUBMB Life 2011, 63:1061-1067.
61. Potron A., Poirel L., Croizé J., Chanteperdrix V., Nordmann P. Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii. Antimicrob. Agents Chemother. 2009, 53:3010-3016.
62. Zarrilli R., Pournaras S., Giannouli M., Tsakris A. Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. Int. J. Antimicrob. Agents 2013, 41:11-19.
63. Brown S., Amyes S. OXA β-lactamases in Acinetobacter: the story so far. J. Antimicrob. Chemother. 2006, 57:1-3.
64. OXA-143, in Acinetobacter baumannii from Brazil: a case report. J. Antimicrob. Chemother. 2012, 67:2531-2532.
65. Higgins P.G., Poirel L., Lehmann M., Nordmann P., Seifert H. OXA-143, a novel carbapenem hydrolyzing class D β-lactamase in Acinetobacter baumannii. Antimicrob. Agents Chemother. 2009, 53:5035-5038.
66. Villa J., Marti S., Sanchez-Cespedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J. Antimicrob. Chemother. 2007, 59:1210-1215.
67. Catel-Ferreira M., Nehme R., Molle V., Aranda J., Bouffartigues E., Chevalier S., Bou G., Jouenne T., De E. Deciphering the function of the outer membrane protein OprD homologue of Acinetobacter baumannii. Antimicrob. Agents Chemother. 2012, 56:3826-3832.
68. Wieczorek P., Sacha P., Hauschild T., Zorawski M., Krawczyk M., TTryniszewska E. Multidrug resistant Acinetobacter baumannii - the role of AdeABC (RND family) efflux pump in resistance to antibiotics. Folia Histochem. Cytobiol. 2008, 46:257-267.
69. Coyne S., Courvalin P., Perichon B. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob. Agents Chemother. 2011, 55:947-953.
70. Drawz S.M., Bonomo R.A. Three decades of β-lactamase inhibitors. Clin. Microbiol. Rev. 2010, 23:160-201.
71. Watkins R.R., Papp-Wallace K.M., Drawz S.M., Bonomo R.A. Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance. Front. Microbiol. 2013, 4:392.
72. Drawz S.M., Papp-Wallace K.M., Bonomo R.A. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob. Agents Chemother. 2014, 58:1835-1846.
73. Lucasti C., Popescu I., Ramesh M.K., Lipka J., Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J. Antimicrob. Chemother. 2013, 68:1183-1192.
74. Vazquez J.A., González Patzán L.D., Stricklin D., et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr. Med. Res. Opin. 2012, 28:1921-1931.
75. Coleman K. Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors. Curr. Opin. Microbiol. 2011, 14:550-555.
76. Tan Q., Ogawa A.M., Painter R.E., Park Y.W., Young K., DiNinno F.P. 4,7-Dichloro benzothien-2-yl sulfonylaminomethyl boronic acid: first boronic acid-derived beta-lactamase inhibitor with class A, C, and D activity. Bioorg. Med. Chem. Lett. 2010, 20:2622-2624.
77. Buynak J.D. β-Lactamase inhibitors: a review of the patent literature (2010-2013). Expert Opin. Ther. Pat. 2013, 23:1469-1481.
78. Faridoon, Ul Islam N. An update on the status of potent inhibitors of metallo-β-lactamases. Sci. Pharm. 2013, 81:309-327.
79. Bhardwaj Ashima K., Mohanty Priyabrata Bacterial efflux pumps involved in multidrug resistance and their inhibitors: rejuvenating the antimicrobial chemotherapy. Recent Pat. Antiinfect Drug Discov. 2012, 7:73-89.
80. Pagès J.M., Amaral L. Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. Biochim. Biophys. Acta 2009, 1794:826-833.
81. Kaitin K.I. Deconstructing the drug development process: the new face of innovation. Clin. Pharmacol. Ther. 2010, 87:356-361.
82. Huh A.J., Kwon Y.J. "Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J. Control. Release 2011, 156:128-145.
83. Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 2013, 65:36-48.
84. Xiong M.H., Bao Y., Yang X.Z., Zhu Y.H., Wang J. Delivery of antibiotics with polymeric particles. Adv. Drug Deliv. Rev. 2014, 78:63-76.
85. Hadinoto K., Chewo S. Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa. Colloids Surf. B: Biointerfaces 2014, 116:772-785.
86. Hsu L.Y., Wijaya L., Tan B.H. Management of healthcare-associated methicillin-resistant Staphylococcus aureus. Expert Rev. Anti-Infect. Ther. 2005, 3:893-905.
87. Saravolatz L.D., Markowitz N., Arking L., Pohlod D., Fisher E. Methicillin-resistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak. Ann. Intern. Med. 1982, 96:11-16.
88. Udo E.E., Pearman J.W., Grubb W.B. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J. Hosp. Infect. 1993, 25:97-108.
89. CDC Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. JAMA 1999, 282:1123-1125.
90. DeLeo F.R., Otto M., Kreiswirth B.N., Chambers H.F. Community-associated meticillin-resistant Staphylococcus aureus. Lancet 2010, 375:1557-1558.
91. Otto M. MRSA virulence and spread. Cell. Microbiol. 2012, 14:1513-1521.
92. Jimenez J.N., Ocampo A.M., Vanegas J.M., Rodriguez E.A., Mediavilla J.R., Chen L., Muskus C.E., Vélez L.A., Rojas C., Restrepo A.V., Ospina S., Garcés C., Franco L., Bifani P., Kreiswirth B.N., Correa M.M. CC8 MRSA strains harboring SCCmec type IVc are predominant in Colombian hospitals. PLoS ONE 2012, 7:e38576.
93. Tattevin P., Diep B.A., Jula M., Perdreau-Remington F. Long-term follow-up of methicillin-resistant Staphylococcus aureus molecular epidemiology after emergence of clone USA300 in San Francisco jail populations. J. Clin. Microbiol. 2008, 46:4056-4057.
94. Tattevin P., Diep B.A., Jula M., Perdreau-Remington F. Methicillin-resistant Staphylococcus aureus USA300 clone in long-term care facility. Emerg. Infect. Dis. 2009, 15:953-955.
95. Graveland H., Duim B., van Duijkeren E., Heederik D., Wagenaar J.A. Livestock-associated methicillin-resistant Staphylococcus aureus in animals and humans. Int. J. Med. Microbiol. 2011, 301:630-634.
96. Guardabassi L., O'Donoghue M., Moodley A., Ho J., Boost M. Novel lineage of methicillin-resistant Staphylococcus aureus, Hong Kong. Emerg. Infect. Dis. 2009, 15(12):1998-2000.
97. Mulders M.N., Haenen A.P.J., Geenen P.L., Vesseur P.C., Poldervaart E.S., Bosch T., Huijsdens X.W., Hengeveld P.D., Dam-Deisz W.D., Graat E.A., Mevius D., Voss A., Van De Giessen A.W. Prevalence of livestock-associated MRSA in broiler flocks and risk factors for slaughterhouse personnel in The Netherlands. Epidemiol. Infect. 2010, 138:743-755.
98. Garcia-Graells C., Antoine J., Larsen J., Catry B., Sko R., Denis O. Livestock veterinarians at high risk of acquiring methicillin-resistant Staphylococcus aureus ST398. Epidemiol. Infect. 2012, 140:383-389.
99. Kluytmans J.A.J.W. Methicillin-resistant Staphylococcus aureus in food products: cause for concern or case for complacency?. Clin. Microbiol. Infect. 2010, 16:11-15.
100. de Boer E., Zwartkruis-Nahuis J.T.M., Wit B., Huijsdens X.W., de Neeling A.J., Bosch T., van Oosterom R.A., Vila A., Heuvelink A.E. Prevalence of methicillin-resistant Staphylococcus aureus in meat. Int. J. Food Microbiol. 2009, 134:52-56.
101. van Loo I.H.M., Diederen B.M.W., Savelkoul P.H.M., Woudenberg J.H., Roosendaal R., van Belkum A., Lemmens-den Toom N., Verhulst C., van Keulen P.H., Kluytmans J.A. Methicillin-resistant Staphylococcus aureus in meat products, the Netherlands. Emerg. Infect. Dis. 2007, 13(11):1753-1755.
102. Leclercq R., Derlot E., Duval J., Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N. Engl. J. Med. 1988, 319:157-161.
103. Uttley A.H., Collins C.H., Naidoo J., George R.C. Vancomycin-resistant enterococci. Lancet 1988, 1:57-58.
104. Low D.E., Keller N., Barth A., Jones R.N. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 2001, 32(Suppl. 2):S133-S145.
105. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR Morb. Mortal. Wkly Rep. 1993, 42:597-599.
106. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 2004, 32:470-485.
107. Coque T.M., Tomayko J.F., Ricke S.C., Okhyusen P.C., Murray B.E. Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Antimicrob. Agents Chemother. 1996, 40:2605-2609.
108. Thal L.A., Chow J.W., Mahayni R., et al. Characterization of antimicrobial resistance in enterococci of animal origin. Antimicrob. Agents Chemother. 1995, 39:2112-2115.
109. Bonten M.J., Willems R., Weinstein R.A. Vancomycin-resistant enterococci: why are they here, and where do they come from?. Lancet Infect. Dis. 2001, 1:314-325.
110. Sorensen T.L., Blom M., Monnet D.L., Frimodt-Moller N., Poulsen R.L., Espersen F. Transient intestinal carriage after ingestion of antibioticresistant Enterococcus faecium from chicken and pork. N. Engl. J. Med. 2001, 345:1161-1166.
111. van den Bogaard A.E., Bruinsma N., Stobberingh E.E. The effect of banning avoparcin on VRE carriage in The Netherlands. J. Antimicrob. Chemother. 2000, 46:146-148.
112. Aarestrup F.M., Seyfarth A.M., Emborg H.D., Pedersen K., Hendriksen R.S., Bager F. Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark. Antimicrob. Agents Chemother. 2001, 45:2054-2059.
113. Lim S.K., Kim T.S., Lee H.S., Nam H.M., Joo Y.S., Koh H.B. Persistence of vanA-type Enterococcus faecium in Korean livestock after ban on avoparcin. Microb. Drug Resist. 2006, 12:136-139.
114. Sirot D., Sirot J., Labia R., Morand A., Courvalin P., Darfeuille-Michaud A., Perroux R., Cluzel R. Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel β-lactamase. J. Antimicrob. Chemother. 1987, 20:323-334.
115. Bradford P.A. Extended-spectrum b-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 2001, 14:933-951.
116. Pfaller M.A., Segreti J. Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases. Clin. Infect. Dis. 2006, 42(Suppl. 4):S153-S163.
117. Jones R.N., Biedenbach D.J., Gales A.C. Sustained activity and spectrum of selected extended-spectrum b-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Int. J. Antimicrob. Agents 2003, 21:1-7.
118. Gales A.C., Sader H.S., Jones R.N. Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000). Diagn. Microbiol. Infect. Dis. 2002, 44:289-299.
119. Bell J.M., Turnidge J.D., Gales A.C., Pfaller M.A., Jones R.N. Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn. Microbiol. Infect. Dis. 2002, 42:193-198.
120. Winokur P.L., Canton R., Casellas J.M., Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin. Infect. Dis. 2001, 32(Suppl. 2):S94-S103.
121. Pitout J.D.D., Laupland K.B. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 2008, 8:159-166.
122. Apisarnthanarak A., Kiratisin P., Saifon P., Kitphati R., Dejsirilert S., Mundy L.M. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study. Am. J. Infect. Control 2007, 35:606-612.
123. Apisarnthanarak A., Hsu L.Y., Khawcharoenporn T., Mundy L.M. Carbapenem-resistant Gram-negative bacteria: how to prioritize infection prevention and control interventions in resource-limited settings?. Expert Rev. Anti-Infect. Ther. 2013, 11:147-157.
124. Gupta N., Limbago B.M., Patel J.B., Kallen A.J. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin. Infect. Dis. 2011, 53:60-67.
125. Kumarasamy K.K., Toleman M.A., Walsh T.R., Bagaria J., Butt F., Balakrishnan R., Chaudhary U., Doumith M., Giske C.G., Irfan S., Krishnan P., Kumar A.V., Maharjan S., Mushtaq S., Noorie T., Paterson D.L., Pearson A., Perry C., Pike R., Rao B., Ray U., Sarma J.B., Sharma M., Sheridan E., Thirunarayan M.A., Turton J., Upadhyay S., Warner M., Welfare W., Livermore D.M., Woodford N. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 2010, 10:597-602.
126. Mataseje L.F., Bryce E., Roscoe D., Boyd D.A., Embree J., Gravel D., Katz K., Kibsey P., Kuhn M., Mounchili A., Simor A., Taylor G., Thomas E., Turgeon N., Mulvey M.R. Canadian Nosocomial Infection Surveillance Program. Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP). J. Antimicrob. Chemother. 2012, 67:1359-1367.
127. Vatopoulos A. High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece-a review of the current evidence. Euro Surveill. 2008, 13. (pii:8023).
128. Leavitt A., Navon-Venezia S., Chmelnitsky I., Schwaber M.J., Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob. Agents Chemother. 2007, 51:3026-3029.
129. Hidron A.I., Edwards J.R., Patel J., Horan T.C., Sievert D.M., Pollock D.A., Fridkin S.K. Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 2008, 29:996-1011. National Healthcare Safety Network Team.
130. Rhomberg P.R., Jones R.N. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection program: a 10-year experience in the United States (1999-2008). Diagn. Microbiol. Infect. Dis. 2009, 65:414-426.
131. Yigit H., Queenan A.M., Anderson G.J., Domenech-Sanchez A., Biddle J.M., Steward C.D., Alberti S., Bush K., Tenover F.C. Novel carbapenem hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2011, 45:1151-1161.
132. Yong D., Toleman M.A., Giske C.G., Cho H.S., Sundman K., Lee K., Walsh T.R. Characterization of a new metallo-beta-lactamase gene, bla (NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 2009, 53:5046-5054.
133. Struelens M.J., Monnet D.L., Magiorakos A.P., Santos O'Connor F., Giesecke J. New Delhi metallo-beta-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. Euro Surveill. 2010, 15. (pii:19716).
134. Maltezou H.C., Giakkoupi P., Maragos A., Bolikas M., Raftopoulos V., Papahatzaki H., Vrouhos G., Liakou V., Vatopoulos A.C. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece). J. Infect. 2009, 58:213-219.
135. Savard P., Perl T.M. A call for action: managing the emergence of multidrug-resistant Enterobacteriaceae in the acute care settings. Curr. Opin. Infect. Dis. 2012, 25:371-377.
136. Williamson D.A., Sidjabat H.E., Freeman J.T., Roberts S.A., Silvey A., Woodhouse R., Mowat E., Dyet K., Paterson D.L., Blackmore T., Burns A., Heffernan H. Identification and molecular characterisation of New Delhi metallo-β-lactamase-1 (NDM-1)- and NDM-6-producing Enterobacteriaceae from New Zealand hospitals. Int. J. Antimicrob. Agents 2012, 39:529-533.
137. Ying C.M., Ling T.K., Lee C.C., Ling J.M. Characterization of carbapenem-resistant Acinetobacter baumannii in Shanghai and Hong Kong. J. Med. Microbiol. 2006, 55:799-802.
138. Koh T.H., Tan T.T., Khoo C.T., Ng S.Y., Tan T.Y., Hsu L.Y., Ooi E.E., Van Der Reijden T.J., Dijkshoorn L. Acinetobacter calcoaceticus-Acinetobacter baumannii complex species in clinical specimens in Singapore. Epidemiol. Infect. 2012, 140:535-538.
139. Routsi C., Pratikaki M., Platsouka E., Sotiropoulou C., Nanas S., Markaki V., Vrettou C., Paniara O., Giamarellou H., Roussos C. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Infection 2010, 38:173-180.
140. Le Hello S., Falcot V., Lacassin F., Mikulski M., Baumann F. Risk factors for carbapenem-resistant Acinetobacter baumannii infections at a tertiary care hospital in New Caledonia, South Pacific. Scand. J. Infect. Dis. 2010, 42:821-826.
141. Asensio A., Cantón R., Vaqué J., Calbo-Torrecillas F., Herruzo R., Arribas J.L., Sáenz M.C. Prevalence of infection by carbapenem-resistant Acinetobacter baumannii in Spain (1999-2005). Enferm. Infecc. Microbiol. Clin. 2008, 21:199-204. Grupo de Trabajo EPINE.
142. Peleg A.Y., Franklin C., Bell J.M., Spelman D.W. Emergence of carbapenem resistance in Acinetobacter baumannii recovered from blood cultures in Australia. Infect. Control Hosp. Epidemiol. 2006, 27:759-761.
143. Kim Y.J., Kim S.I., Kim Y.R., Hong K.W., Wie S.H., Park Y.J., Jeong H., Kang M.W. Carbapenem-resistant Acinetobacter baumannii: diversity of resistant mechanisms and risk factors for infection. Epidemiol. Infect. 2012, 140:137-145.
144. Dejsirilert S., Tiengrim S., Sawanpanyalert P., Aswapokee N., Malathum K. Antimicrobial resistance of Acinetobacter baumannii: six years of National Antimicrobial Resistance Surveillance Thailand (NARST) surveillance. J. Med. Assoc. Thail. 2009, 92:S34-S45.
145. Su C.H., Wang J.T., Hsiung C.A., Chien L.J., Chi C.L., Yu H.T., Chang F.Y., Chang S.C. Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: association with hospital antimicrobial usage. PLoS ONE 2012, 7:e37788.
146. Akinci E., Colpan A., Bodur H., Balaban N., Erbay A. Risk factors for ICU-acquired imipenem-resistant Gram-negative bacterial infections. J. Hosp. Infect. 2005, 59:317-323.
147. Cisneros J.M., Rodríguez-Baño J., Fernández-Cuenca F., Ribera A., Vila J., Pascual A., Martínez-Martínez L., Bou G., Pachón J. Risk-factors for the acquisition of imipenem-resistant Acinetobacter baumannii in Spain: a nationwide study. Clin. Microbiol. Infect. 2005, 11:874-879. Spanish Group for Nosocomial Infection (GEIH) for the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).
148. Playford E.G., Craig J.C., Iredell J.R. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J. Hosp. Infect. 2007, 65:204-211.
149. Aydemir H., Celebi G., Piskin N., Oztoprak N., Keskin A.S., Aktas E., Sumbuloglu V., Akduman D. Mortality attributable to carbapenem-resistant nosocomial Acinetobacter baumannii infections in a Turkish university hospital. Jpn. J. Infect. Dis. 2012, 65:66-71.
150. Higgins P.G., Dammhayn C., Hackel M., Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 2010, 65:233-238.
151. Kim D.H., Choi J.Y., Kim H.W., Kim S.H., Chung D.R., Peck K.R., Thamlikitkul V., So T.M., Yasin R.M., Hsueh P.R., Carlos C.C., Hsu L.Y., Buntaran L., Lalitha M.K., Song J.H., Ko K.S. Spread of carbapenem-resistant Acinetobacter baumannii global clone 2 in Asia and AbaR-type resistance islands. Antimicrob. Agents Chemother. 2013, 57:5239-5246.